Small Molecules Targeting Mitochondria: A Mechanistic Approach to Combating Doxorubicin-Induced Cardiotoxicity

Area of Science:

• Biochemistry
• Cardiology
• Pharmacology

Background:

• Doxorubicin (Dox) is a vital chemotherapy agent, but its use is limited by dose-dependent cardiotoxicity.
• Mitochondrial dysfunction is a primary driver of Dox-induced cardiotoxicity (DIC), involving oxidative stress and apoptosis.
• Targeting mitochondria offers a potential strategy to mitigate Dox-related heart damage.

Purpose of the Study:

• To review small molecules that preserve mitochondrial function and offer cardioprotection against Dox.
• To analyze the mechanisms by which these agents counteract Dox-induced cardiotoxicity.
• To highlight the therapeutic potential of mitochondria-targeted therapies for cancer patients.

Main Methods:

• Literature review of studies on small molecules and Dox-induced cardiotoxicity (DIC).
• Analysis of mechanisms including ROS reduction, mitochondrial membrane potential stabilization, and modulation of apoptotic pathways.
• Evaluation of evidence for improved cardiovascular outcomes in cancer patients.

Main Results:

• Small molecules can reduce reactive oxygen species (ROS) production and stabilize mitochondrial membrane potential.
• These agents enhance mitochondrial biogenesis and modulate cell survival/apoptosis pathways.
• Mitochondria-targeted therapies demonstrate potential in preventing or reducing DIC.

Conclusions:

• Mitochondria-targeted small molecules offer a promising strategy to mitigate Dox-induced cardiotoxicity (DIC).
• Preserving mitochondrial function is key to safeguarding cardiovascular health during chemotherapy.
• Further research into these mechanisms can lead to safer Dox utilization and better patient outcomes.